Clinical trial · Expanded Access
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
NCT06132191CI-TRIAL-00097653approved for marketingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Provide expanded access of cemiplimab in patients with solid tumors
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma (BCC) | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.85 |
| Cutaneous Squamous Cell Carcinoma (CSCC) | Skin Squamous Cell Carcinoma | ALIAS | 0.85 |
| Non-Small Cell Lung Cancer (NSCLC) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cemiplimab | Drug | Cemiplimab | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility record
- sex
- ALL
- stdAges
- CHILD
- ADULT
- OLDER_ADULT
- criteria
- null
- maximumAge
- null
- minimumAge
- null
- healthyVolunteers
- null
References
Publications (0)
Data not yet available
No reference posted for this study.